The role of whole genome sequencing in characterizing the mechanism of action of para-aminosalicylic acid and its resistance by Satta, Giovanni et al.
Title: The role of whole genome sequencing in characterizing the mechanism of action 1 
of para-aminosalicylic acid and its resistance 2 
 3 
Authors:  4 
Giovanni Satta1,2, Adam A. Witney3, Neelu Begum1, Julio Ortiz Canseco1, Andrew N. 5 
Boa4, Timothy D. McHugh1 6 
 7 
Affiliations: 8 
1. Centre for Clinical Microbiology, University College London 9 
2. Department of Infectious Disease, Imperial College London 10 
3. Institute for Infection and Immunity, St George's University of London 11 
4. Department of Chemistry, University of Hull 12 
 13 
Corresponding Author: 14 
Dr Giovanni Satta FRCPath MBBS MSc MBA PhD DTM&H 15 
Consultant in infectious diseases and medical microbiology 16 
Imperial College Healthcare NHS Trust, St. Mary's Hospital, Salton House, Level 3 - 17 
Room 15 London W2 1NY 18 




AAC Accepted Manuscript Posted Online 22 June 2020
Antimicrob. Agents Chemother. doi:10.1128/AAC.00675-20
Copyright © 2020 American Society for Microbiology. All Rights Reserved.
















Para-aminosalicylic acid (PAS) remains one of the drugs of last resort for the treatment 24 
of tuberculosis, but its mechanism of action is not completely understood yet. The main 25 
aim of this project was to identify new potential mechanisms of action and resistance 26 
to PAS by performing whole genome sequencing (WGS) on PAS-resistant laboratory 27 
mutants. A new variant in the folC gene has been identified as well as some other 28 
mutations that require further studies.    29 















Para-aminosalicylic acid (PAS), also known as 4-aminosalicylic acid, was one of the 30 
first chemotherapeutic agents to be used against tuberculosis (TB) and it is currently 31 
an orphan drug only available to treat extensively drug-resistant disease[1]. Despite 32 
being used for decades, its mechanism of action is not completely understood. It 33 
has been proposed that, being an analogue of para-amino benzoic acid (PABA), 34 
PAS competes with PABA for dihydropteroate synthase, interfering in the process 35 
of folate synthesis[2]. A study using transposon mutagenesis identified mutations in 36 
the thyA gene that were also present in clinical isolates resistant to PAS [3]. The 37 
gene thyA encodes for a thymidylate synthase enzyme (essential for DNA 38 
replication and repair) and its deletion has been demonstrated to confer resistance 39 
to PAS[4]. Other studies have also identified various missense mutations 40 
in folC (encoding a dihydrofolate synthase) and ribD (alternative dihydrofolate 41 
reductase) that conferred resistance to PAS in laboratory and clinical isolates of M. 42 
tuberculosis [5] [6] [7]. Nevertheless, mutations in folC were detected in only 34.8% 43 
of resistant clinical isolates, whilst mutations of thyA and ribD were detected in 44 
26.0% and 5.8%, respectively [6]. Hence, other mechanisms of resistance to the 45 
drug might exist. Efflux pumps have also been described conferring cross-resistance 46 
to PAS and other chemotherapeutic agents including streptomycin [8].  The main 47 
aim of this work was to investigate potential new mechanisms of action and 48 
resistance to PAS by performing whole genome sequencing (WGS) on PAS-49 
resistant laboratory mutants. 50 
 51 
PAS resistant laboratory mutants of reference strain H37Rv were spontaneously 52 
selected by growth on 7H10 medium with the addition of PAS. M. tuberculosis was 53 
cultured in 20 mL aliquots of sterile 7H9 broth and incubated for 14 days, achieving 54 















log phase and a colony count of 0.5-1 McFarland (150-300X106/mL). Following the 55 
incubation period, the bacteria were concentrated by centrifugation at 10,000g for 56 
ten minutes and the entire sediment was inoculated onto pre-prepared 7H10 plates 57 
containing different concentrations of PAS, 2 µg/ml and 4 µg/ml (the critical 58 
concentration for PAS is 2 µg/ml) [9]. After incubation at 37 °C for at least 14 days, 59 
spontaneous mutants grew on the plates and they were then selected for 60 
sequencing. All selected mutants and the parent reference H37Rv were sub-61 
cultured on Lowenstein-Jensen (LJ) slopes, DNA was extracted using the CTAB 62 
(cetyl trimethylammonium bromide) method and WGS analysis performed as 63 
previously described [10].  64 
 65 
It was possible to grow only one PAS mutant for each critical concentration (2 µg/ml 66 
and 4 µg/ml) from a culture containing 150-300X106/mL bacteria. As the experiment 67 
was repeated in two separate occasions, we were able to select four mutants in 68 
total. These resistant mutants were designated PAS2 (1st and 2nd) and PAS4 (1st 69 
and 2nd).  70 
When compared to the sequenced reference strain H37Rv, a total of seven non-71 
synonymous single nucleotide polymorphisms (SNPs) affecting four different genes 72 
were identified in the four PAS resistant mutants. Both PAS4 mutants showed 73 
variants in the folC gene, a known mutation in position 2747141 and a new mutation 74 
in position 2747195 (Table 1). There was evidence of a V58I variant in the Rv3218 75 
gene in both the PAS2 and one of the PAS4 mutants, but reads matching both the 76 
reference and variant base were found at this site and this call is uncertain. At low 77 
coverage, a total of twenty-seven SNPs were also found in the rrs and rrl genes (16s 78 















and 23s RNA genes) of all four mutants. However, these SNPs remain unconfirmed 79 
due to the low coverage. 80 
WGS has been previously used to determine the mechanism of action of 81 
antituberculous agents. In the case of bedaquiline (BDQ), the authors selected and 82 
sequenced BDQ resistant Mycobacterium smegmatis strains and identified 83 
mutations in the proton pump of adenosine triphosphate (ATP) synthase associated 84 
with resistance [11]. In the case of PAS-resistant mutants, WGS analysis indicated 85 
that it is necessary to revisit the folate metabolic pathway to fully understand our 86 
data. The folate biosynthetic pathway starts when the aromatic precursor chorismate 87 
is converted to p-aminobenzoic acid (PABA) and coupled with pteridine to generate 88 
dihydropteroate. The protein encoded by folC, dihydrofolate synthetase, adds 89 
glutamate to the dihydropteroate forming dihydrofolate [12]. Mutations in the folC 90 
gene have been associated with PAS resistance but in fewer than 35% of the cases, 91 
whilst the same authors could not find any mutation in the folP1 gene [4]. Here, both 92 
PAS4 resistant mutants gained a SNP affecting the folC gene (Table 1). The 93 
mutation E153A has been previously reported to confer resistance to PAS [12] and 94 
it is already included in some online database for WGS analysis. The new mutation 95 
D135G has not been previously associated with PAS resistance. However, it has 96 
been shown to be important for the linkage of α-helices in the folC protein structure 97 
[13] and it could represent an additional mechanism of resistance to PAS. It is 98 
interesting to note that such variants in the folC gene did not develop in the PAS2 99 
mutants at lower concentration raising the hypothesis of an association with high 100 
level resistance as noted in other antituberculous drugs [14]. This could have some 101 
clinical relevance in that higher levels of resistance could be managed and 102 
potentially prevented by optimizing the dosage as previously described by other 103 















authors [15]. It is also worth highlighting the fascinating finding (albeit unconfirmed) 104 
of rrs and rrl genes mutations. These genes are linked to the ribosomes, including 105 
the conversion from tRNAMet to tRNAfMet (Figure 1) and hence the synthesis of 106 
proteins in general. This would hypothetically resemble the mechanism of resistance 107 
of streptomycin, even if streptomycin resistance is more frequently associated with 108 
mutations in the rpsL gene, rather than the rrs/rrl [16]. As PAS and streptomycin 109 
have been companion drugs for decades and at a time when next generation 110 
sequencing technologies were not available, this mechanism of action/resistance 111 
may have been missed and it is certainly worth further research. Our analysis is 112 
based on only four resistant mutants as it was difficult to select PAS-resistant 113 
mutants in the laboratory. This could be due to the essentiality of genes involved 114 
and the negative impact that a deletion and/or an altered gene function would have 115 
on cell survival [17]. In addition, the presence of mutations in the genome needs 116 
additional confirmation that such mutations encode for significant metabolic 117 
changes. 118 
After nearly 70 years of clinical use of PAS, WGS analysis may help in elucidating 119 
its mechanism of action, but further studies are still needed.  120 
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Tables and figures 209 
Gene Function SNP position 


























Possible osmoprotectant binding 
lipoprotein; conserved membrane 
protein 
   
4205442 
At low coverage, a total of twenty-seven SNPs were found in the rrs and rrl genes (16s and 23s RNA genes) 
of all four mutants. Data not shown due to low coverage.  
 210 
Table 1: List of SNPs in the PAS resistant mutants. Table above shows the genes involved in the PAS-resistant 211 
mutants, with the respective function and SNP position in the genome. Only high quality non-synonymous and 212 















intergenic SNPs were considered (*mixed base calls and therefore lower quality evidence in these mutants for these 213 
sites). The hypothetical amino acid changes caused by the SNP are also shown in brackets. 214 





















Figure 1: Folate metabolism in M. tuberculosis. Abbreviations: DHPPP, 7,8-218 
dihydropterin pyrophosphate; PABA, para-aminobenzoic acid; H2Pte, 219 
dihydropteroate; H2PteGlu, dihydrofolate; H4PteGlu, tetrahydrofolate; C1-220 
H4PteGlu, various single-carbon-modified species of H4PteGlu; ThyX, thymidylate 221 
synthase; tRNAMet, methionyl-tRNA; tRNAfMet, N-formylmethionyl-tRNA; Fmt, 222 
formyl-methionine transferase.  223 
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